A review of carbamazepine and valproate use in a psychiatric hospital in Thailand

被引:0
作者
Silpakit, Chatchawan [1 ]
Silpakit, Orawan [2 ]
机构
[1] Ramathibodi Hosp, Dept Psychiat, Rama VI Rd, Bangkok 10400, Thailand
[2] Srithanya Hosp, Dept Mental Hlth, Div Neurol, Nonthaburi, Thailand
来源
ASEAN JOURNAL OF PSYCHIATRY | 2007年 / 8卷 / 01期
关键词
carbamazepine; valproate; psychiatric hospital;
D O I
暂无
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Objective: To review the clinical use of carbamazepine (CBZ) and valproate (VPA) in a psychiatric hospital in Thailand. Design: Retrospective medical record review. Setting: An outpatient department of a psychiatric hospital in the central part of Thailand. Participants: Patients prescribed either CBZ or VPA in January 2005 and continued the medications for at least six months. Results: There were 277 cases receiving either CBZ or VPA during the study period, 57.8% were male. CBZ was prescribed in 92 cases, VPA 185 cases. Mood stabilizing was the most common indication. However, more than 50% were prescribed the medications for other off-license indications. The doses were not slowly titrated. Means of current dose were lower than the recommended doses. A small number of minor adverse drug reactions were found. Weight gain was under recognized. Conclusion: Off-license uses of CBZ and VPA were common. Sub-therapeutic doses were frequently prescribed. The benefits of lower doses in this off-license use need an extensive evaluation. Guidelines for the use of CBZ and VPA in psychiatric patients may be useful for rational drug use program.
引用
收藏
页码:9 / 14
页数:6
相关论文
共 44 条
  • [1] Alderfer BS, 2003, J CLIN PSYCHIAT, V64, P3
  • [2] Aripiprazole, a novel atypical antipsychotic drug
    Argo, TR
    Carnahan, RM
    Perry, PJ
    [J]. PHARMACOTHERAPY, 2004, 24 (02): : 212 - 228
  • [3] Carbamazepine in comparative trials - Pharmacokinetic characteristics too often forgotten
    Arroyo, S
    Sander, JWAS
    [J]. NEUROLOGY, 1999, 53 (06) : 1170 - 1174
  • [4] BASAN A, 2004, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD004028.PUB2
  • [5] Efficacy of divalproex therapy for schizoaffective disorder
    Bogan, AM
    Brown, ES
    Suppes, T
    [J]. JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2000, 20 (05) : 520 - 522
  • [6] A randomized, placebo-controlled 12-month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder
    Bowden, CL
    Calabrese, JR
    McElroy, SL
    Gyulai, L
    Wassef, A
    Petty, F
    Pope, HG
    Chou, JCY
    Keck, PE
    Rhodes, LJ
    Swann, AC
    Hirschfeld, RMA
    Wozniak, PJ
    [J]. ARCHIVES OF GENERAL PSYCHIATRY, 2000, 57 (05) : 481 - 489
  • [7] Valproic acid hepatic fatalities .3. US experience since 1986
    Bryant, AE
    Dreifuss, FE
    [J]. NEUROLOGY, 1996, 46 (02) : 465 - 469
  • [8] Adjunctive divalproex and hostility among patients with schizophrenia receiving olanzapine or risperidone
    Citrome, L
    Casey, DE
    Daniel, DG
    Wozniak, P
    Kochan, LD
    Tracy, KA
    [J]. PSYCHIATRIC SERVICES, 2004, 55 (03) : 290 - 294
  • [9] Citrome Leslie, 2003, Psychopharmacol Bull, V37 Suppl 2, P74
  • [10] Comprehensive review of the psychiatric uses of valproate
    Davis, LL
    Ryan, W
    Adinoff, B
    Petty, F
    [J]. JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2000, 20 (01) : 1S - 17S